ALPMF - Astellas receives positive CHMP opinion for investigational nonhormonal treatment VEOZA
2023-10-13 09:38:00 ET
More on Astellas Pharma ADR
- Astellas: Earnings Power, Asset Factors Attractive, Reiterate Hold On Valuation
- Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript
- Merck succeeds in Phase 3 trial for bladder cancer therapy
- Apellis spikes as Astellas posts long-term data for rival product
- Seeking Alpha’s Quant Rating on Astellas Pharma ADR
For further details see:
Astellas receives positive CHMP opinion for investigational nonhormonal treatment VEOZA